Carl Icahn happy with Board Representation at Amylin Pharma
| February 10th, 2010 | ||
| Contributed by: Hedge Fund Solutions LLC | ||
| Shareholder activist investor Carl Icahn stated on January 25th that he will not seek additional representation on Amylin Pharmaceuticals, Inc.’s (NASDAQ: AMLN) board because enough board members approve of re-nominating two candidates that were appointed last year after a proxy contest with Mr. Icahn’s Icahn Associates and Eastbourne Capital Management LLC. Icahn’s hedge funds currently hold 12,971,328 shares of Amylin or 9.43% of shares outstanding. Hedge Fund Solutions previously covered AMLN in numerous Catalyst Research Reports, highlighting Icahn’s and Eastbourne Capital’s (12.5%) successful attempt to replace two board members up for election in 2009. | ||
For Detailed Investor Profiles on these Investors, click below: |
Eastbourne Capital Management |
Icahn Associates (Carl Icahn) |
Related People: Alexander J. Denner;
Related Entities: Black Bear Hedge Funds;
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles; Hedge Fund Resources and Featured Partner News
Add a Comment |
More Recent Headlines
Nautical Capital Management Unveils New Commodity-Based Strategies |
BarCap’s Study Shows Marketing and Communications Spending Up |
One Step Backwards? |
Castle Hill Asset Management spins-off from Ignis and launches first Hedge Fund |
CalSTRS' Efforts Improve Climate Risk Transparency |
Hedge Fund Hire Report: RWC Partners, John W. Henry & Co, Harvard’s Endowment, and Moore Capital Management |
Hornstein Partners Fund launches with $10 million |
BlueGold Capital Denies Responsibility for Oil Sell Off |
Phil Falcone makes a killing on new Harbinger Credit Fund |
BlueCrest Capital Management to close off BlueTrend Fund to new investors |
